- AVEO, Delcath hit hard by FDA reviews
- Questions raised over clinical value of Sanofi's semuloparin ahead of US FDA committee meeting
- Delcath ocular melanoma drug-device combo too risky, ODAC says
- FDA ODAC refuses to back AVEO RCC drug tivozanib
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.